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Abstract: Epigenetic regulation of gene transcription by small molecule inhibitors of histone 
deacetylases (HDAC) is a novel cancer therapy. Vorinostat (Zolinza™) is the ﬁ  rst FDA approved 
HDAC-inhibitor for treatment of patients with cutaneous T cell lymphoma (CTCL) who have 
progressive, persistent or recurrent disease on or following two systemic therapies. Vorinostat 
was active against solid tumors and hematologic malignancies as intravenous and oral prepara-
tions in Phase I development. In two Phase II trials, vorinostat was safe and effective at an oral 
dose of 400 mg/day with an overall response rate of 24%–30% in refractory advanced patients 
with CTCL including large cell transformation and Sézary syndrome (SS). The common side 
effects of vorinostat, similar in all studies, included gastro-intestinal symptoms, fatigue, and 
thrombocytopenia and the most common serious events were thrombosis. Vorinostat, in com-
bination with other agents such as radiation therapy and chemotherapy, have shown synergistic 
or additive effects in a variety of cancers in clinical trials.
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Mycosis fungoides and Sezary syndrome: 
Pathogenesis and features
Cutaneous T-cell lymphomas (CTCL) are a clinically heterogeneous group of post-
thymic lymphomas, accounting for the majority of all lymphomas arising in skin. Myco-
sis fungoides (MF) and Sézary syndrome (SS), the most common variants, are still rare 
with an annual incidence of 3 to 4 new cases per million or 1200 new cases per year in 
the United States (Giardi et al 2004; Kim et al 2005). The next most common entities 
are the CD30+ lymphoproliferative disorders: lymphomatoid papulosus and anaplastic 
large T-cell lymphoma (ALCL). Sub-cutaneous panniculitic T-cell lymphoma and NK-T 
cell lymphomas are quite rare, and more aggressive. Cutaneous T-cell lymphomas that 
do not ﬁ  t into one of these categories are peripheral T-cell lymphomas, unclassiﬁ  ed 
and are described on the basis of immunohistochemical phenotype.
Mycosis fungoides (MF) and Sézary syndrome (SS) are deﬁ  ned by their cutane-
ous presentation and the accumulation of a T helper memory/effector subset with a 
CD4+,CD8−, CD45RO+CLA+ phenotype (Kazakov et al 2004). In many patients, MF 
starts as an indolent and chronic dermatitis in the sun shielded areas and a diagnostic 
biopsy is difﬁ  cult to obtain for years. In order to diagnose MF, there must be atypical 
lymphocytes within the epidermis, and the presence of CD4+CD8+ cells and clon-
ality are supporting characteristics. In SS, the atypical cells have lost epidermotropism 
and are found around the dermal vessels (Diwan et al 2005).
Mycosis fungoides is staged using the Tumor Nodes Metastasis classiﬁ  cation 
schema which is used to stage patients and to predict disease prognosis. MF may Biologics: Targets & Therapy 2007:1(4) 378
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progress to a leukemic and erythrodermic condition 
called Sézary syndrome (SS) which requires the presence 
of 1000/μL of atypical circulating cells. Sézary cells 
secrete Th2 cytokines, IL-4 and IL-10, causing loss of cel-
lular immunity due to decreased production of Th1 cytokines, 
interferon gamma and interleukin 2 (IL-2) (Kim et al 2005). 
This results in an atopic state characterized by erythroderma 
and staphylococcus colonization, peripheral eosinophilia, 
increased IgE production, and intractable pruritus. Thus, 
one strategy used to treat MF/SS, is to restore the immune 
Th2Th1 imbalance.
Tan et al ﬁ  rst hypothesized that T-cell proliferation was 
initiated by persistence of chronic antigen stimulation (Tan 
et al 1974). Molecular methods have shown that in MF there 
is emergence of one or more T-cell clones of skin-homing 
CD4+ cells and that with progression to SS, these appear in 
the blood and can be detected by ﬂ  ow cytometry (Vega et al 
2002). If MF/SS is antigen driven, the stimulus would not 
need to be the same in each patient and could be autoantigens 
or environmental and once initiated might not resolve with 
removal of the antigen. That MF/SS patients have class II 
HLA associations with DR5 and DQB*03 alleles does sup-
port genetic predisposition similar to other autoimmune skin 
diseases (Jackow et al 1996).
Infectious agents such as Epstein-Barr virus, cyto-
megalovirus, HTLV-1, and Staphylococcus aureus have 
been hypothesized as possible triggers (Axelrod et al 1992; 
Tokura et al 1995; Jackow et al 1997; Shimakage et al 2001; 
Giardi et al 2004). The observation that the atypical CD4+ 
lymphocytes cluster around epidermal Langerhans cells (the 
Pautrier’s microabcess characteristic of MF) also supports an 
antigen driven immune response (Giardi et al 2004; Diwan 
et al 2005). Immature dendritic cells (Langerhans cells) in 
the epidermis are thought to activate T cells through direct 
contact and providing the stimulus for their clonal expan-
sion by migrating to the dermis (Berger et al 2002). It is 
hypothesized that the loss of activation induced cell death 
following T-cell proliferation through loss of Fas may lead 
to accumulation of the T-cells in skin resulting in chronic 
inﬂ  ammatory lesions (Ni et al 2005).
Tumor cells expressing Fas Ligand may eliminate tumor 
inﬁ  ltrating, cytotoxic CD8+ T-cells, allowing disease pro-
gression to occur (Ni et al 2005). Progression of MF/SS is 
accompanied by clonal dominance of the malignant cells 
(Vega et al 2002) leading to the elaboration of Th2 cyto-
kines (Rook et al 1997), impairment of the hosts’ immune 
response, and further tumor cell growth (Giardi et al 2004; 
Kim et al 2005).
Treatment of early MF
There is a very limited number of FDA-approved therapies 
available to treat patients with MF/SS. However, agents 
that are used for eczema, psoriasis, and other forms of 
lymphoma are used for MF/SS and represent the standard 
of care. Early MF is characterized by eczematous or pso-
riasiform dermatitis limited to less than 10% of the body 
surface. Lesions are often most prominent in sun-shielded 
areas and will fade with exposure to UVB or UVA light. 
Early MF lesions are treated with one or more skin directed 
therapies and are capable of inducing durable complete 
responses. The ﬁ  rst therapy used frequently before MF is 
diagnosed is the application of topical corticosteroids of 
increasing potency. For thicker or hypertrophic lesions, the 
topical retinoid gels or creams may be effective, can reduce 
the time of clearing with phototherapy, but may cause irrita-
tion, especially in intertriginous areas. The response rate of 
targretin gel 1% was 76% in patients not previously treated 
and this agent is the only topical therapy approved for MF 
(Breneman et al 2002). We have found this gel useful for 
MF of the hands or feet (Lain et al 2003) and for aborting 
lymphomatoid papulosis lesions (Kraken et al 2003). In an 
opened label pilot study, tazarotene gel was active as a ste-
roid adjuvant for treatment of MF lesions (Apisarnthanarax 
et al 2004). The topical inducer of interferon, imiquimod 
5%, has produced 50% histologic clearing of MF lesions 
when applied to lesions of 6 patients for 3 days per week 
for 12 weeks (Deeths et al 2005).
Treatment of intermediate 
or refractory early MF
Patients with 10% involvement (IA) who do not respond 
to ﬁ  rst line topical therapies or who have 10% of the body 
surface area I (IB) or dermatopathic nodes (IIA) often need 
more extensive therapies such as topical chemotherapy with 
mustargen, BCNU, or with a combination of skin directed 
therapy plus one or more biological response modiﬁ  ers. 
Agents that are not speciﬁ  cally approved for MF/SS are 
commonly used as the standard of care: topical steroids and 
mustargen, phototherapy, interferons, and chemotherapies. 
For patch disease, narrow band UVB is effective and can 
be effectively combined with topical steroids or retinoids. 
Thick plaque lesions or folliculotropic MF lesions are more 
difﬁ  cult to clear and are treated with PUVA plus interferon 
or an oral retinoid (bexarotene, soriatane, or accutane). Total 
electron beam radiation is reserved for patients who need 
skin palliation or who have extensive skin involvement and Biologics: Targets & Therapy 2007:1(4) 379
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have failed to respond to skin directed therapies, and should 
be followed with a form of maintenance therapy such as 
mustargen, PUVA, or oral bexarotene.
Oral bexarotene and intravenous denileukin diftitox have 
received FDA approval for treatment of the cutaneous mani-
festations of CTCL and are used in this setting, along with 
interferon alpha. Bexarotene monotherapy has a response rate 
of 54% at a dose of 300 mg/m2 in early patients and 45% in 
more advanced patients (Duvic et al 2001). Its dose limiting 
toxicity is hypertriglyceridemia, especially in predisposed 
patients. Use of lower doses of bexarotene is often effective 
in combination therapy and the triglyceridemia can often be 
controlled with addition of an HMG-coA reductase and/or a 
statin (Assaf et al 2006). Alpha interferon is another biologi-
cal response modiﬁ  er that has shown signiﬁ  cant activity for 
MF and SS and may be used in combination with PUVA, 
photopheresis, and retinoids. It is widely used for MF/SS 
but has some dose limiting toxicities such as fever, fatigue, 
low white count, anemia, and hepatitis. Vorinostat, a novel 
histone deacetylase inhibitor, discussed in detail below, has 
also been approved recently and would also be considered to 
be in the category of the biological response modiﬁ  ers, based 
on its known mechanism of action so far and its potential 
ability to synergize with radiation or phototherapy.
Denileukin diftitox (Ontak®), a fusion protein composed 
of IL-2 and diphtheria toxin, is an example of a biologic 
response modiﬁ  er as well as one of the newer targeted 
therapies developed for CTCL. It received FDA approval for 
cutaneous manifestations of CTCL of all stages based on a 
randomized two dose arm controlled multicenter trial show-
ing a response rate of 30% (Olsen et al 2001). Patients with 
tumors (IIB) had signiﬁ  cantly better responses at the higher 
dose of 18 μg/kg/day given for 5 days, every 3 weeks and 
it is a non-immunosuppressive alternative to chemotherapy 
for debulking MF tumors. Complete responses were seen in 
10% of the patients enrolled (Olsen et al 2001). Capillary 
leak syndrome is seen in 20%–30% of patients but may 
be decreased with hydration and acute fusion reactions are 
blocked by steroid pre-medication. Bexarotene and steroids 
may increase CD25 expression on T-cells as measured by 
ﬂ  ow and could suggest synergism (Foss et al 2005). Our 
study suggested that high expression of CD25+ in 20% 
of the tumor cells was associated with higher response rates 
60% compared to 20% of the low expressing patient and 30% 
in the pivotal trial. Additional studies have supported the 
use of this agent for other lymphomas, chronic lymphocytic 
leukemia, graft versus host disease, psoriasis, and elimination 
of tumor suppressor T-regs.
Generalized exfoliative erythroderma (EE) may be 
induced by S. aureus (Deeths et al 2005). MF and SS can 
present with EE, and the diagnosis of SS depends on having 
blood involvement ﬁ  tting the B2 criteria (Atypical circulat-
ing lymphs 1000/μL or presence of a clone of CD4+ 26 or 
7-cells). Extracorporeal photopheresis was approved in 1987 
for the treatment of CTCL patients and signiﬁ  cant responses 
were seen in erythrodermic patients (Lim et al 1995). Pho-
topheresis is usually combined with biological response 
modiﬁ  ers, especially interferon and retinoids, for responses 
approaching 60%–70% (McGinnis et al 2005). Patients with 
refractory or transformed MF and SS who do not respond 
to immune stimulating therapy have a poor prognosis and 
further therapy is usually palliative. There are several active 
targeted agents used in this setting which include nucleoside 
analogues (pentostatin, and the experimental agent forode-
sine), and monoclonal antibody to CD52 Campath H1.
Patients with transformed MF, tumors, or nodal dis-
ease may respond to local radiation, denileukin diftitox, 
nucleoside analogues (gemcitabine, pentostatin), doxil, or 
combination chemotherapy. Various chemotherapy combi-
nations, while effective for a limited time, can also induce 
further immunosuppression leading to line induced sepsis or 
other opportunistic infections. There is a deﬁ  nite need for 
new therapies to treat patients. The recent FDA-approved 
HDAC inhibitor, vorinostat, represents a new strategy for 
targeted therapy of CTCL (Marks et al 2007). As shown in 
two Phase II trials it has efﬁ  cacy in patients who have failed 
prior therapies. This new agent is a biological response modi-
ﬁ  er but can work when chemotherapy has failed and has the 
advantage of being orally administered (Duvic et al 2007). 
Vorinostat is the ﬁ  rst HDAC-inhibitor to be approved for a 
malignancy indication.
Classiﬁ  cation of the HDAC 
and HDAC inhibitors (HDAC-I)
HDAC inhibitors (HDAC-I) are a new class of anti-
neoplastic agents and are currently being evaluated in a 
number of clinical trials for a wide variety of cancer types, 
as monotherapy and in combination with other effective 
modalities. Normal cells have a balance between acetyla-
tion and deacetylation of histones mediated through the 
activity of histone acetyl-transferases (HATs) and histone 
deacetylases (HDACs) (de Ruijter et al 2003; Gregoretti 
et al 2004). HDACs remove acetyl groups on histones 
causing chromatin to be compacted resulting in silencing 
of gene transcription. Cancer cells tend to have over-
expression of HDACs and aberrant recruitment HDACs to Biologics: Targets & Therapy 2007:1(4) 380
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oncogeneic transcription factors causing hypoacetylation 
of core nucleosome histones. Cancer cells may also have 
reduced HAT activity through mutations resulting in silenc-
ing of genes such as tumor suppressors. HDAC-inhibitors 
are small molecules that bind to the active enzymatic sites 
in class I and II zinc containing HDAC enzymes. Depres-
sion of gene transcription by HDAC-I that block removal 
of acetyl-groups permits DNA transcription to occur. 
Although these enzymes are called “histone” acetylases 
and deacetylases, they actually have broad enzymatic 
effects on many other proteins, and predate histones in 
evolution (de Ruijter et al 2003; Gregoretti et al 2004). 
Many genes are suppressed as upregulated in expression 
by HDAC inhibitors.
As shown in Table 1, there are four known classes of 
HDAC- inhibitors based on their chemical structures and the 
prototypes are sodium n-butyrate, a short chain fatty acid; 
vorinostat (SAHA) an organic hydroxamic acid; depsip-
eptide (romidepsin), a bicyclic depsipeptide; and MS-275, 
a benzamide. HDAC-I prevent histone deacetylases from 
catalyzing the hydrolysis of acetyl groups from the amino-
terminal lysine residues of the nucleosomal core histones 
(Figure 1). Athough HDAC-inhibitors can affect speciﬁ  c 
HDAC enzymes, vorinostat has broad class I and II activity 
(Gregoretti et al 2004).
Eighteen HDAC enzymes have been described to date. 
They are divided into three families based on homology to 
yeast HDAC proteins. HDACs 1, 2, 3, 8 are class I (between 
350 and 500 amino acids in length) (de Ruijter et al 2003; 
Gregoretti et al 2004), localized in the nucleus and are inhib-
ited by vorinostat (SAHA) and romidepsin. HDACs 4–7, 
9–11 are class II (about 1000 amino acids in length), found 
in cytoplasm and nucleus, inhibited by vorinostat (SAHA) 
but not romidepsin. HDAC 11 contains conserved residues 
that are shared by both class I and class II enzymes and thus 
is usually classiﬁ  ed as a class I enzyme. Recent phylogenetic 
studies indicate that it represents a separate class of HDACs 
(class IV) (Gregoretti et al 2004; Ledent and Vervoort 2006). 
Class III HDACs are homologous to the yeast “silencing 
information regulator 2” (Sir2) family of deacetylases and 
have a unique catalytic mechanism that requires the cofactor 
nicotinamide adenine dinucleotide (NAD+) (Blander and 
Guarente 2004). Vorinostat is a non-speciﬁ  c agent inhibiting 
the activity of class I (types 1, 2, 3), II (type 6) and IV (type 
11) HDAC enzymes, speciﬁ  cally (Gregoretti et al 2004). 
Romidepsin preferentially inhibits only class I enzymes, 
but is also classiﬁ  ed as a broad spectrum inhibitor because 
it does inhibit Class II enzymes, at higher concentrations 
(Furumai et al 2002).
HDAC-inhibitors – mechanisms 
of action
Acetylation of histones proteins on lysine tails prevents 
close interactions with the DNA backbone and promotes 
a loosening of chromatin structure. This permits access of 
transcription factors to speciﬁ  c promoter regions increasing 
transcription of genes. Although HDAC-I only inﬂ  uence 
1%–2% of genes, genes controlling differentiation, cell 
proliferation, and apoptotic cell death are affected. HDAC 
inhibitors induce the cdk kinase inbitor (p21) causing 
cell cycle arrest leading to death. HDAC inhibitors target 
critical cell-cycle regulatory pathways and may induce 
the expression of various silenced tumor-suppressor genes 
critical in controlling cancer cell growth (Lindemann et al 
2004). HDAC inhibitors trigger both caspase-dependent 
and caspase-independent apoptosis and may be as much as 
1000-fold more toxic to malignant T-cells as to nonmalignant 
cells (Zhang et al 2005). The precise pathway that leads to 
cellular differentiation or apoptosis is not well understood. 
It has also been hypothesized that HDAC inhibitors may 
work as anti-angiogenesis agents though decreasing VEGF 
(Heider et al 2006).
The rationale for clinical use of HDAC inhibitors for 
cancer is based on their anti-proliferative effects: induction 
of differentiation, cell cycle growth arrest, and apoptosis, 
demonstrated for numerous cancer cell-lines in culture and in 
vivo mouse models (Lindemann et al 2004). HDAC-I induces 
the accumulation of acetylated histones and changes gene 
expression (Lindemann et al 2004; Kelly et al 2005; Kelly 
and Marks 2005; O’Connor 2005; Duvic and Zhang 2006). 
However, histone acetylation is seen in all patients’s cells 
and is not correlated with clinical response at least in CTCL 
patients (Zhang et al 2005; Heider et al 2006; Kelly et al 
2005; Duvic and Zhang 2006). HDAC inhibitors have also 
been shown to block deacetylation of non-histone substrates, 
ie,transcriptional factors such as p53, transduction mediators, 
and molecular chaperones all of which may also be important 
Table 1 Structure of HDAC-inhibitors
Short chain fatty acids  Butyrate, phenylbutyrate, valproic acid AN-9
Hydroxamic acids  Trichostatin A, vorinostat (SAHA)*, pyroxamide,
  LBH-589*, PXD-101*, LAQ-824
Cyclic Romidepsin*  (depsipeptide)
Benzamides MS-275
*Activity in CTCLBiologics: Targets & Therapy 2007:1(4) 381
Vorinostat and cutaneous T-cell lymphoma
in the anti-cancer effects (Butler et al 2000, 2002; Lindemann 
et al 2004; Kelly and Marks 2005; O’Connor 2005).
In addition to the potential use of HDAC inhibitor 
monotherapy for cancer, they may also be combined 
eventually and more effectively with other conventional 
chemotherapeutics and/or biological agents (Cohen et al 
1999, 2002; He et al 2001; Reddy et al 2004). HDAC inhibi-
tors have already been shown to be additive or synergistic 
with anthracyclines (Marchion et al 2004), tumor necrosis 
factor-related apoptosis-inducing ligand (TRAIL) (Butler 
et al 2006), and all-trans-retinoic acid (Zhang et al 2005). 
They are efﬁ  cient radiation modifying agents and therefore, 
have been proposed as possible clinical radiation sensitizers 
or protectors (Moradei et al 2005).
Vorinostat and romidepsin have shown in vitro and in 
vivo cytotoxic activity against various tumors which made 
them attractive to bring into clinical trials (Gore and Carducci 
2000). In Phase I and II clinical trials, these HDAC-I were 
active in mycosis fungoides and peripheral T cell lymphoma 
patients (Querfeld et al 2005). They received orphan drug 
designation from the FDA for the treatment of advanced 
CTCL. Based the similar results in two Phase II trials, vori-
nostat was approved for the cutaneous manifestations of 
CTCL in October 2006.
Vorinostat: “SAHA”
Vorinostat (Zolinza™; Merck, Whitehouse Station, NJ, 
USA), was previously known as suberoylanilide hydroxamic 
acid or SAHA. The drug is an orally bioavailable inhibitor of 
Class I and II HDACs (Gregoretti et al 2004). It is described 
chemically as N-hydroxy-N-′phenyloctanediamide, a small 
molecule with the molecular formula C14H20N2O3 (shown in 
Figure 2) and a molecular weight of 264.32. It has no chiral 
centers and is non-hygroscopic. It is very slightly soluble in 
water and freely soluble in dimethyl sulfoxide with a pH of 
6.6 in saturated water. The discovery and pre-clinical devel-
opment of vorinostat was a collaboration between Breslow, 
Professor of Chemistry at Columbia, and Marks, Rifkind and 
Richon, Cell Biology at Sloan-Kettering and Phase I Clinical 
Trials at Memorial Sloan Kettering with Kelly Scher, and 
colleagues (Marks and Breslow 2007). Subsequently, Phase I 
clinical trials were conducted by Aton Pharmaceuticals prior 
to its being acquired by Merck in April 2004. Vorinostat 
comes in 100 mg capsules.
Preclinical studies
In preclinical studies, vorinostat was shown to cause accu-
mulation of acetylated histones, induce cell-cycle arrest and 
apoptosis in a broad range of cancer cell lines, including 
Sezary cells (Zhang et al 2005). Vorinostat also showed 
antitumor activity in leukemia, lymphoma, and solid-tumor 
models in vivo (Vrana et al 1999; Kelly et al 2003, 2005; 
Garcia-Manero et al 2005; Sakajiri et al 2005; Zhang et al 
2005; O’Connor et al 2006).
Marks et al ﬁ  rst demonstrated the efﬁ  cacy of SAHA 
(vorinostat) in vivo in nude mice bearing a human prostate 
histone tail
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cancer cell (CWR22) xenograft (Marks et al 2001; 
Marks and Dokmanovic 2005; Marks and Jiang 2005). 
The intraperitoneal administration of vorinostat daily for 
21 days completely inhibited tumor cell growth at doses 
that had no detectable toxic effects on normal cells as 
determined by hematological studies and extensive autopsy 
examination (Butler et al 2000). Subsequently, orally or 
parenterally administered vorinostat was shown effective 
in inhibiting tumor growth in a carcinogen-induced mam-
mary tumor in rats, a human neuroblastoma xenograft in 
mice, a transgenic mouse model of therapy-resistant acute 
promyelocytic leukemia, and a carcinogen-induced lung 
cancer in mice, all with little or no toxicity (Desai et al 
2003).
Mechanism of vorinostat in CTCL cells
Vorinostat inhibits HDACs of class I (types 1, 2, 3) and II 
(type 6) at about 50 nM concentrations (Richon et al 1998). 
It arrests cell growth of a wide variety of transformed 
cells in culture at 2.5–5.0 μM, including Sezary and MF 
cell lines (Moradei et al 2005; Zhang et al 2005). Class I 
HDACs are primarily nuclear in localization and ubiqui-
tous. Class II HDAC expression is more tissue restricted; 
these HDACs shuttle between the nucleus and the cyto-
plasm, and some are primarily cytoplasmic proteins. At 
concentrations inducing growth arrest of both normal and 
transformed cultured cells, vorinostat causes cell death 
of only the transformed cells (including neuroblastoma, 
melanoma, leukemia, multiple myeloma and breast, pros-
tate, lung, ovary, colon) suggesting selective and broad 
anti-cancer effects. As shown in Figure 3, by inhibiting 
HDAC activity, vorinostat facilitates transcription of genes 
governing growth arrest, caspase-dependent apoptotic cell 
death and/or caspase-independent autophagic cell death of 
transformed cells (Richon et al 2000; Rosato et al 2003; 
Gui et al 2004; Guo et al 2004; Lindemann et al 2004; 
Shao et al 2004; Zhang et al 2005). Normal cells are up 
to tenfold more resistant to vorinostat-induced cell death 
compared with transformed cells (Marks and Jiang 2005; 
Ungerstedt et al 2005; Zhang et al 2005). Vorinostat causes 
the accumulation of acetylated histones in both normal and 
transformed cells, and histone acetylation, as measured in 
an assay using peripheral mononuclear cells, has proved 
to be a predictive marker for HDAC inhibitory activity of 
the drug in vivo (Kelly and Marks 2005).
Zhang et al showed that vorinostat at 1–5 μM selectively 
causes apoptosis of CTCL cell lines and SS/MF patients’ 
PBL compared to healthy donors’ PBL (Zhang et al 2005). 
This difference in sensitivity to vorinostat-induced apopto-
sis appears not to be caused by a difference in the ability to 
inhibit HDAC activity because accumulation of acetylated 
histones occurs in both tumor and normal cells (Kelly et al 
Figure 3 Proposed mechanism of reaction.
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2005; Marks and Jiang 2005; Ungerstedt et al 2005; Zhang 
et al 2005). Vorinostat induced tumor cell apoptosis at 
concentrations (1–5 μM) to which normal cells are relatively 
resistant (Zhang et al 2005). This was associated with an 
accumulation of acetylated histones, increased p21WAF1 
and bax, decreased Stat6 and phosphor-Stat6, and activation 
of caspase 3 (Zhang et al 2005). This study agrees with the 
ﬁ  nding that romidepsin (FK228), also induces apoptosis of 
Hut78 CTCL cells in vitro (Piekarz et al 2004). The results 
presented by Ungerstedt et al (2005) indicate that vorinostat 
may cause an accumulation of reactive oxygen species (ROS) 
and caspase activation in transformed but not normal cells as 
well as an increase in the level of Trx, a major reducing pro-
tein for many targets, in normal cells but not in transformed 
cells (Zhang et al 2005).
In vitro studies of CTCL cell lines revealed that vorinostat 
at concentrations associated with apoptosis resulted in induc-
tion of expression of p21waf1 (Zhang et al 2005). P21 is a 
cdk inhibitor responsible for cell cycle arrest and apoptosis 
induced by HDAC inhibitors (Mei et al 2004; Somech et al 
2004). Although upregulation of p21waf1 was demonstrated 
in response to vorinostat, immunoblot analysis showed that 
this effect was independent of the tumor suppressor p53. In 
MF skin lesions and cell lines in vitro, the nuclear to cyto-
plasmic expression of p-Stat 3 protein shifted (Duvic and 
Zhang 2006). Stat proteins belong to a family of transcrip-
tion factors that, once activated, are believed to contribute to 
oncogenesis by stimulating cell proliferation and preventing 
apoptosis (Sommer et al 2004; Turkson 2004). They have 
been shown to be constitutively expressed in CTCL cell 
lines, and therefore are interesting targets of vorinostat action. 
Vorinostat at concentrations capable of producing apoptosis, 
decreased the expression of Stat6 and phosphor-Stat-6 (but 
not Stat3 and phosphor-Stat3) were seen in CTCL cell lines 
and peripheral blood lymphocytes from SS patients (Duvic 
and Zhang 2006).
Phase I clinical trials for vorinostat 
in solid tumors and hematologic 
malignancies
Preclinical studies in mice and rabbits showed that a 2-hour 
infusion of vorinostat at the maximal administered dose 
of 3000 mg/m2/day for 3 days produced no drug related 
deaths or organ toxicities. On the basis of this and a mouse 
tumor xenograft model (efﬁ  cacy at 150 mg/m2/day), Kelly 
et al at Memorial Sloane Kettering performed the ﬁ  rst dose 
escalation study of intravenous vorinostat given by 2 hour 
IV infusion in 37 patients with advanced cancer (Kelly et al 
2003). The starting dose of 75 mg/m2/day was escalated to 
900 mg/m2/day with no dose limiting toxicities (He et al 
2001). In part B of the trial, vorinostat was administered 
for 3 days every 21 days for solid tumors patients (n = 7) 
and 5 days per week for 1–3 weeks for those patients with 
hematological malignancies (n = 12). The maximum tolerated 
dose in hematologic malignancies was 300 mg/m2/day × 5 
days per week for 3 weeks. Median duration of response 
was 6.4 weeks (range, 1.6–40 weeks). The half-life was 
21–58 minutes. There was dose related increase in the AUC, 
and the plasma concentration exceeded 2.5 μM at all dose 
levels (Kelly 2003). Acetylated H3 histones accumulated in 
peripheral blood mononuclear cells and in tumor biopsies 
at all doses. The duration of acetylation increased with dose 
escalation. The drug was generally well tolerated with some 
fatigue and gastrointestinal symptoms noted.
In 73 patients with hematologic or solid tumors treated 
with oral vorinostat in Phase I (Kelly et al 2005), the maxi-
mum tolerated dose was deﬁ  ned as 400 mg daily, or 200 
mg BID for continuous daily dosing, or 300 mg BID for 3 
consecutive days per week. Dose limiting thrombocytope-
nia was reported in 87% of the patients with hematologic 
malignancies compared to only 44% of the patients with 
solid-tumors, and was more severe in the former group (Kelly 
et al 2005). There was anti-tumor activity in lymphomas and 
in patients with solid tumors, including thyroid, renal cell, 
mesothelioma, laryngeal, and urothelial carcinomas.
Thirty-ﬁ  ve patients with hematologic malignancies were 
treated in a Phase I trial with either intravenous (n = 12) or 
oral vorinostat (n = 23) at continuous doses ranging from 
200 mg/daily to 300 mg/twice daily (O’Connor et al 2006). 
Oral vorinostat showed good oral availability and favorable 
pharmacokinetics. Of interest, the IV formulation gave a four 
fold higher C max while oral administration produced signiﬁ  -
cantly higher (22 fold) AUC values. Vorinostat was active 
in different hematologic malignancies: Hodgkin disease, 
diffuse large B-cell lymphomas, and 3 patients with CTCL. 
One MF patient experienced a 4 month partial response. 
Dose limiting toxicities observed were nausea, vomiting, 
diarrhea, anorexia, dehydration, fatigue, and myelosuppres-
sion. Patients with hematologic malignancies appeared to be 
more sensitive to thrombocytopenia and myelosuppressive 
effects (thrombocytopenia, neutropenia, and leukopenia) 
(O’Connor et al 2006). Thrombocytopenia with vorinostat 
was accompanied by hypolobular and decreased numbers of 
megakaryocytes, suggesting an impairment in differentiation, 
and recovery was observed in 3–7 days.Biologics: Targets & Therapy 2007:1(4) 384
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Dose ranging Phase II trial of oral 
vorinostat
In light of the favorable preclinical studies and the response 
of CTCL patients to oral vorinostat in Phase I, a single center, 
non-randomized, Phase II dose ranging trial was initiated. 
The purpose of the trial was to determine response rate and 
duration, safety, and tolerability of oral vorinostat in heavily 
pretreated patients with refractory CTCL (Duvic et al 2007). 
Thirty-three patients with refractory or relapsed CTCL 
(stages IA-IVB) unresponsive to at least one conventional 
systemic therapy were enrolled into one of three dosing 
cohorts (Duvic et al 2007). Four patients received treatment 
in 2 cohorts but were considered only once for efﬁ  cacy.
The patients were highly pre-treated with a median of 
5 prior therapies (range 1–15). Twenty-nine (83%) had 
advanced stage MF (IIB) and one third had Sézary Syn-
drome, deﬁ  ned as erythroderma with blood involvement. 
Twenty-nine of the 33 patients had received prior chemo-
therapy, 22 had received bexarotene, and 14 had received 
denileukin diftitox (Table 2). Patients were treated sequen-
tially with one of three oral dosing schedules and the demo-
graphics were similar among the three cohorts (Table 3). 
The ﬁ  rst cohort received 400 mg daily, the second received 
300 mg twice daily (for 3 days with 4 days’ rest), and the 
third received 300 mg twice daily for 14 days, with 7 days 
off followed by 200 mg twice daily for maintenance. The 
MF stages and response for each cohort as well as the dose 
modiﬁ  cation schedule are shown in Table 4.
The primary efﬁ  cacy end point of the study was the 
complete and partial response rate (CR, PR). However, the 
study also evaluated the time to response, time to progressive 
disease, response duration, pruritus relief, and safety. The 
response to therapy was categorized according to the World 
Health Organization criteria (Miller et al 1981) as complete 
response (CR), partial response (PR), stable disease (SD), 
or progressive disease (PD). The skin involvement was 
calculated as body surface area (BSA) involvement with 
patch, plaque, or tumor disease.
Considering unique patients for an intent-to-treat analy-
sis, 8 out of 33 or 24% of the patients achieved a documented 
PR deﬁ  ned as a 50% reduction in skin score and no increase 
in other disease sites. There were no complete responses. 
An additional 11 patients had pruritus relief, stable disease, 
or both such that 19 (58%) of 33 study patients received 
clinical beneﬁ  t from the drug. Responses to vorinostat were 
observed in a broad spectrum of the study population, includ-
ing a patient with early IA refractory MF, one patient with 
advanced tumors with histologic large-cell transformation, 
and patients with nodal and/or blood involvement (Table 5). 
One elderly patient with large cell lymphoma tumors had 
very fast response in his existing tumors, but new tumors 
formed while he was on therapy (Figure 4). There was no 
difference in response rate in patients who had received prior 
bexarotene or not.
Secondary objectives were to determine the duration of 
response and to evaluate the safety and tolerability of vori-
nostat in these patients. The median duration of response 
overall and in patients with stage IIB or higher CTCL was 
15.1 weeks (106 days) and ranged from 9.4 to 19.4 weeks 
(66–136 days). The median duration of response was numeri-
cally lowest in group 2 who received intermittent dosing 
Table 2 Vorinostat in CTCL: Patient demographicsa
Demographic No.  of  patients  %
No. of patients  33 
Sex
 Male  18  55
 Female  15  45
Median age, years  67
Performance status 
 Stage  IA  1  3
 Stage  IB  2  6
 Stage  IIA  1  3
 Stage  IIB 29  88
Prior therapy
 Chemotherapy  29  88
 Ontak  14  42
 Bexarotene  22  67
Failed ECP+  15 45
aPhase 2A 
Abbreviation: ECP, extracorporeal photopheresis.
Table 3 Phase II oral vorinostat: intent to treat response of 24% 
(8/33)
  400 mg qd  300 mg bid × 300  mg  bid  × 2w 
 (n  = 13)  3–5 d/wk   400 mg qd 
   (n  = 11)  (n = 9)
Partial response   4 (31%)  1 (9%)  3 (33%)
Marked (patients)  2  1  3 
Median PR duration   15  16  13
(range/weeks) (8–24) (8–24)  (3–21)
Mean time to PR   11   4   11
(weeks)
LN regression  7 of 9  3 of 8  5 of 9
at 4 wks (patients) 
50%↓ pruritus   9 of 11  8 of 12  4 of 8 
(patients)
Abbreviations: LN, lymph node; PR, partial response.Biologics: Targets & Therapy 2007:1(4) 385
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(9.4 weeks [66 days]) and highest in group 1 treated with 
400 mg daily (16.1 weeks [113 days]).
The most common major toxicities that were possibly or 
probably related to oral vorinostat therapy were fatigue and 
gastrointestinal symptoms, including diarrhea, altered taste, 
nausea, and dehydration from not eating/drinking (Table 6). 
Thrombocytopenia was dose limiting in cohort 3 following 
the higher dose of 300 mg twice daily for 14 days. Overall, 
the daily dose of 400 mg vorinostat orally provided the most 
favorable risk-beneﬁ  t proﬁ  le and dose of 400 mg daily was 
selected for evaluation in a second Phase IIb multi-center 
trial (Duvic et al 2007; Olsen et al 2007).
Phase II B multi-center single arm trial 
of oral vorinostat in CTCL patients
Phase IIb was conducted as an open-label, multi-center trial 
of oral vorinostat at 400mg daily in patients with IB-IVA 
MF/SS (Olsen et al 2007). Two dose modiﬁ  cations were 
allowed: 300 mg daily or 300 mg daily for 5 days per week. 
Safety assessments were done with NCI Common Terminol-
ogy Criteria for Adverse Events v3.0. Patients were eligible 
with MF/SS Stage IB to IVB that was progressive, persistent, 
or recurrent on or following more than 2 prior systemic 
therapies. One must have contained bexarotene unless the 
patient was intolerant. Patients with ECOG performance 
status of 0–2, adequate hematologic, hepatic, and renal 
function were included. Patients with prior use of HDAC 
inhibitor or anticancer treatment within 3 weeks of study 
entry were excluded. Table 7 demonstrates baseline CTCL 
stage prior to dosing.
Approximately 30% of patients with treatment refractory 
advanced MF/SS  Stage IIB had at least a partial response 
and one patient with tumors had a complete long lasting 
response (Figures 4 and 5). The median time to response 
was less than 2 months. Clinically long lasting responses 
were observed and 15 patients stayed on the drug for over 
a year. Median response duration and time to progression 
in advanced patients (IIB or ) were not reached but were 
estimated to be at least 6.1 and 9.8 months, respectively. 
Median time to progression in all patients was 4.9 months. 
Vorinostat provided pruritus relief in 30% of patients includ-
ing 25% of those who did not meet the criteria for objective 
cutaneous response.
The 400 mg dose was well tolerated since less than 
15% of patients (n = 10) required dose reduction. Only 
11% of patients had related serious adverse events: throm-
bosis, anemia, thrombocytopenia, increased creatinine, 
gastrointestinal hemorrhage, ischemic stroke, syncope, 
and streptococcal bacteremia. The most common drug 
related adverse events were gastrointestinal symptoms 
(diarrhea (49%), nausea (43%), anorrhexia (26%), dys-
geusia, dry mouth, vomiting, constipation, anorexia), or 
fatigue (46%), thrombocytopenia, weight decrease, alo-
pecia, muscle spasms, increase in creatinine, anemia, and 
chills. Most adverse events were grade 2 or less. Grade 3 
events included fatigue (5%), pulmonary embolism (5%), 
thrombocytopenia (5%) and nausea (4%). There were three 
deaths in the study, including one sudden death on day 2 
(Olsen et al 2007). Based on the Phase I and II studies, 
Table 4 Oral vorinostat dosing and dose modiﬁ  cation schedule
Treatment group  Dosing schedule  First dose reduction  Second dose reduction
1  400 mg every day*  350 mg every day  300 mg every day
2  300 mg twice daily × 3 d per wk ×  250 mg × 3 d/wk  200 mg twice daily × 3 d/wk
  4 wk, then 5 d every wk 
3  Ind:  300 mg twice daily × 14 d with  200 mg twice daily  200 mg twice daily × 5 d/wk
  7 d rest; mtnc; 200 mg twice daily 
Abbreviation: Ind, indicates induction; mtnc, maintenance.
*Initial 3 patients treated at 250 mg/m2/day
Table 5  Vorinostat in CTCL: Response ratesa
  400 mg qd  300 mg bid × 300  mg  bid   
 (n  = 13)  3–5 d/wk   400 mg qd 
   (n  = 11)  (n = 9)
Partial response   4 (31%)  1 (9%)  3 (33%)
marked (patients)  2  1  3 
Median PR duration   15  16   13
(range/weeks) (8–24)  (8–24)  (3–21)
Mean time to PR   11   4   11
(weeks)
LN regression  7 of 9  3 of 8  5 of 9
at 4 wks (patients) 
50%↓ pruritus   9 of 11  8 of 12  4 of 8
(patients) 
aPhase 2A 
Abbreviations: LN, lymph node; PR, partial response.Biologics: Targets & Therapy 2007:1(4) 386
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on October 6, 2006, the FDA approved a New Drug 
Application for vorinostat for the treatment of cutaneous 
manifestions of CTCL in patients who have progressive, 
persistent, or recurrent disease on or following two prior 
systemic treatments.
Pharmacokinetics and caveats
Vorinostat is 71% bound to plasma proteins over a 
range of 0.5 to 50 μg/mL (Kelly and Marks 2005). It is 
metabolized by glucuronidation and hydrolysis followed 
by B-oxidation. The two serum metabolites are not active 
Baseline Termination at 5 wks 
Figure 4 Vorinostat in CTCL: resolved large-cell tumor (*Phase 2A).
Table 6 ZolinzaTM (vorinostat) clinical or laboratory adverse events occurring in CTCL patients (incidence 10% of patients) 
  Zolinza 400-mg once daily (n = 86)   
Adverse events  All grades  Grades 3–5*
 n  %  n  % 
Fatigue 45  52.3  3  3.5
Diarrhea 45  52.3  0  0.0
Nausea 35  40.7  3  3.5
Dysgeusia 24  27.9  0  0.0 
Thrombocytopenia 22  25.6  5  5.8 
Anorexia 21  24.4  2  2.3 
Weight decreased  18  20.9  1  1.2 
Muscle spasms  17  19.8  2  2.3 
Alopecia 16  18.6  0  0.0 
Dry mouth  14  16.3  0  0.0 
Blood creatinine increased  14  16.3  0  0.0 
Chills 14  16.3  1  1.2 
Vomiting 13  15.1  1  1.2 
Constipation 13  15.1  0  0.0 
Dizziness 13  15.1  1  1.2 
Anemia 12  14.0  2  2.3 
Decreasd appetite  12  14.0  1  1.2 
Peripheral edema  11  12.8  0  0.0 
Headache 10  11.6  0  0.0 
Pruritus 10  11.6  1  1.2 
Cough 9  10.5  0  0.0 
Upper respiratory infection  9  10.5  0  0.0 
Pyrexia 9  10.5  1  1.2
*No grade 5 events were reported.
Table summarizes the frequency of speciﬁ  c adverse events, regardless of causality, in CTCL patients using the National Cancer Institute-Common Terminology Criteria for 
Adverse Events, version 3.0 (Olsen et al 2001; Foss et al 2005).Biologics: Targets & Therapy 2007:1(4) 387
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and are excreted through metabolism. The mean half-life 
is about 2.0 hours for vorinostat and the O-glucuronide 
metabolite. It is not an inhibitor of CYP drug metabolizing 
enzymes but there is potential for suppression of CYP2C9 
and CYP3A at concentrations above 10 μM (Desai et al 
2003).
Lab abnormalities seen in patients taking 400 mg in 
the clinical trials included increased serum glucose in 
69%, transient increases in creatinine levels in 46.5%, and 
proteinuria in 51.4%.
Vorinostat should not be taken by nursing or pregnant 
women as it could harm the fetus. It was not studied in 
patients with hepatic or renal impairment. Patients under 
age 18 were not included in the trials. Patients on vorinostat 
should be encouraged to maintain adequate hydration to 
compensate for the GI symptoms.
Other HDAC inhibitors currently 
in clinical trials for CTCL (Table 8)
Romidepsin (depsipeptide)
Depsipeptide, (E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-
4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraaza
bicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentanone, is a 
bicyclic pentapeptide isolated from the soil bacterium 
Chromobacterium violaceum. Romidepsin or depsipeptide 
(FK228) (Gloucester Pharmaceuticals) is a class I novel 
HDAC inhibitor currently in Phase II clinical trials and 
demonstrates clinical activity in patients. Depsipeptide 
has been shown to induce differentiation, cause G1 and 
G2/M cell cycle arrest and apoptosis, increase expression 
of p21 and cyclin E, decrease expression of cyclin D1 and 
c-myc, and cause hypophosphorylation of Rb (Sandor et al 
2000; Picardo et al 2004; Piekarz et al 2004; Piekarz and 
Bates 2004).
In a Phase I trial of intravenous depsipeptide conducted 
at the National Cancer Institute, 3 patients with cutaneous 
T-cell lymphoma had a partial response, and 1 patient with 
peripheral T-cell lymphoma, unspeciﬁ  ed, had a complete 
response. Sézary cells isolated from patients after treat-
ment had increased histone acetylation (Piekarz et al 2001). 
Clinically, following treatment with depsipeptide, there was 
a rapid decrease of circulating Sézary cells and improvement 
of skin erythema and edema.
To date, over 400 cancer patients have received depsipep-
tide in Phase I and II studies. Ongoing clinical investigations 
include Phase II studies including a pivotal trial in cutaneous 
Table 7 Zolinza™ (vorinostat) Study 1: Baseline patient charac-
teristics (all patients as treated) 
Characteristics Vorinostat  (n  = 74)
CTCL stage, n (%) 
IB (14.9%)
IIA 2  (2.7%)
IIB 19  (25.7%)
III 22  (29.7%)
IVA 16  (21.6%)
IVB 4  (5.4%)
Clinical Characteristics 
Number of prior systemic treatments, median
(range) 3.0  (1.0,  12.0)
Figure 5  Vorinostat in CTCL: stage IVA Sézary and keratoderma partial response (*Phase 2A).
Baseline Week 4 Week 12Biologics: Targets & Therapy 2007:1(4) 388
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T-cell lymphoma and another in peripheral T-cell lymphomas. 
Common adverse events are myelotoxicity, asthenia, nausea, 
vomiting, and cardiac repolarization effects and occasional 
cardiac dysrhythmias including QTc prolongation. In cuta-
neous T-cell lymphoma patients, an objective response was 
observed in 10 of 28 evaluable patients, including 3 patients 
with complete response (CR) and 7 with partial response 
(PR), for an overall response rate of 36%.
PXD-101 or bellinostat
PXD-101 (CuraGen) is a low molecular weight HDAC 
inhibitor with a sulfonamide-hydroxamide structure. A 
Phase I open label, dose escalation, safety, PK, and PD 
study of intravenous PXD101 was conducted in patients with 
advanced cancer. Sequential dose cohorts of 3–6 patients 
were examined (150, 300, 600, 900, and 1200 mg/m2). An 
expanded cohort at 1000 mg/m2 was recruited for IV and 
oral testing. The main drug-related adverse events were 
fatigue, nausea, vomiting (infusion-related) and phlebitis. 
Other adverse events included headache, diarrhea, constipa-
tion, and dyspnea. No hematological toxicity was identiﬁ  ed. 
Dose limiting toxicities of Grade 3 fatigue at 600 mg/m2, 
atrial ﬁ  brillation (spontaneously reversible) at 1200 mg/m2, 
Grade 3 diarrhea and lethargy prevented completion of a 
cycle at 1200 mg/m2. The presumptive maximum tolerated 
dose was 1000 mg/m2. Four patients had stable disease 
for 2, 3, 4, 5 cycles respectively. Preliminary data with 
oral dosing showed good tolerability. Pharmacodynamic 
analysis showed histone H4 hyperacetylation in peripheral 
blood mononuclear cells following PXD-101 intravenous 
administration lasting from 6–24 hours post-dose (Steele 
and Vidal 2005).
LBH 589
LBH-589 (Novartis) is a novel HDAC Inhibitor, similar 
to SAHA, but with a longer half-life. There is an ongoing 
Phase I trial of CTCL patients with advanced stage or who 
had progressed following prior systemic therapy evaluat-
ing oral LBH-589 every Monday, Wednesday, and Friday 
at either 30 mg or 20 mg in a 28-days treatment cycle 
(Prince et al 2006). The 30 mg dose was dose limiting. 
Oral LBH589 was continued until progressive disease 
(PD) or unacceptable toxicity. Of 10 patients enrolled to 
date, one was enrolled in the 30 mg cohort and nine in the 
20 mg cohort. Two patients attained CRs, 4 had a PR, and 
3 had SD before progressing, and one had PD. Therefore, 
responses were seen in 6 out of 10 patients treated with 
oral LBH (Prince et al 2006) in the Phase I study. A Phase 
II clinical trial will evaluate the oral formulation in this 
disease indication.
Conclusion
Cancer may arise through multiple defects in the expression 
and/or function of proteins controlling cell proliferation, 
death, and migration. T-cell malignancies remain challenging 
to treat due to the essential role of T-cells for host immune 
function.
Histone deacetylase inhibitors, including vorinostat, 
have the potential to modulate the transcription of multiple 
genes and pathways, yet are selective and efﬁ  cacious as 
anti-cancer agents. Acetylation of histones, tumor sup-
pressors, and transcription factors are thought to underlie 
the ability of vorinostat and other HDAC-inhibitors to 
selectively induce tumor cell apoptosis and growth arrest 
(Bolden et al 2006). HDAC-I should probably be classiﬁ  ed 
as biological response modiﬁ  ers, along with retinoids and 
interferons. With different speciﬁ  city assigned to each of 
the 18 HDACs, the potential effects of HDAC-I are as yet 
largely unknown.
Based on preliminary responses of CTCL patients 
in Phase I trials, we performed a dose ranging study of 
Table 8  HDAC-Is in clinical trials for CTCL
HDAC-I in clinical 
trials for CTCL
Dosage Favorability Limitations
SAHA 400 mg PO daily No IV access, no risk of sepsis, 
high tolerability
Fatigue, thrombocytopenia, pulmonary embolus, 
nausea
Depsipeptide 14 mg/m2 IV day 1, 8, 15 of 
each month
Rapid decrease of Sezary cells 
and erythroderma
IV access with higher risk of sepsis, cardiac 
effects such as QT prolongation and arrhythmia
PXD-101 1000 mg/m2 every 3 weeks No hematological toxicity was 
identiﬁ  ed
IV access with higher risk of sepsis, atrial ﬁ  brilla-
tion, diarrhea, fatigue
LBH 589 20 mg or 30 mg PO MWF 
in a 28 days cycle
No IV access, no risk of sepsis Diarrhea, atrial ﬁ  brillation, fatigue, neutropenia, 
thrombocytopenia, anemiaBiologics: Targets & Therapy 2007:1(4) 389
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oral vorinostat in heavily pretreated CTCL patients and 
observed the most dramatic responses in patients with 
large cell transformation and Sézary syndrome. This 
clinical observation is supported by the selectivity of 
vorinostat for malignant cells in vitro. Oral vorinostat 
was well tolerated at a dose of 400 mg daily and had a 
rapid onset of action (Olsen et al 2007). The drug also 
improved skin, nodal, and blood involvement as well as 
reducing pruritus. This signiﬁ  cantly impacts quality of life 
in SS and MF patients. The side effects of vorinostat are 
well tolerated, and quickly reversible. Even in advanced 
CTCL patients who had limited treatment options, vori-
nostat was well tolerated, with fatigue and gastrointestinal 
symptoms being the most common side effects at lower 
doses. Thrombocytopenia was dose limiting at the highest 
doses but was reversible.
For the treatment of patients with MF and SS who have 
failed traditional therapies, vorinostat is an important new 
therapeutic option with an overall response rate of about 
30%. It was active in patients resistant to chemotherapy and 
has the advantage of being taken orally, avoiding line sepsis 
that can accompany chemotherapy. Advanced MF patients 
often have hyper-coagulable states and caution is indicated 
in patients with a prior history of deep vein thrombosis or 
patients on warfarin therapy. Low platelets are seen at the 
highest concentrations but are reversible when the drug is 
held.
Although EKG changes including ST-T wave changes 
and QT prolongation were observed, they were not clinically 
signiﬁ  cant. Before starting HDAC-I therapy it is advised 
to monitor and if necessary correct the K+ and Mg+ ion 
concentrations. Although there may be a class effect with 
respect to cardiac toxicity, there may be differences among 
HDAC-inhibitors.
Vorinostat is indicated for the treatment of cutaneous 
manifestations in patients with cutaneous T-cell lymphoma 
(CTCL) who have progressive, persistent or recurrent disease 
on or following two systemic therapies.
Future direction of vorinostat
As of 7 March 2007, according to the National Institutes of 
Health Clinical Trials.gov website, there are 41 other clinical 
trials recruiting patients for vorinostat alone or in combina-
tion for a wide range of cancer types. Of these trials, 36 are 
recruiting patients and 5 are approved but not yet recruiting 
patients. Vorinostat has activity in multiple other solid and 
hematologic malignancies and is ﬁ  rst in its class of HDAC-
inhibitor therapy for cancer. HDAC inhibitors may prove 
even more effective when they are combined with other 
agents such as retinoids, ie, bexarotene, phototherapy and 
extracorporeal photophoresis with not-overlapping toxici-
ties (Table 9). Vorinostat in combination studies with other 
agents such as radiation therapy, epirubicin, and ﬂ  uorouracil 
have shown synergistic or additive effects in a variety of 
cancers (Table 10), so the future is very exciting and there 
is unlimited potential for novel approaches to be developed 
(Almenara et al 2002; Nimmanapalli et al 2003; Marchion 
et al 2004; Ocker et al 2005; Bolden et al 2006; Lakshmi-
kanthan et al 2006).
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Table 9 Proposed HDAC inhibitor combination strategies in 
CTCL 
HDACi* + bexarotene: all stages
HDACi* + ECP + bexarotene: Sézary syndrome
HDACi* + methylation inhibitors
HDACi* + chemotherapy for induction and Tx
of advanced disease
Topical HDACi* for early-stage disease
* Vorinostat and/or depsipeptide.
Table 10 Vorinostat in combination studies
Combination Cell  lines  Activity  Reference
Vorinostat + Radiation  Prostate (LNCaP)  Synergistic  Lakshmikanthan, 2006
Vorinostat + Epirubicin  Breast (MCF-7, SKBr3)  Synergistic  Marchion, 2004
Vorinostat + 5-Fluorouracil + irinotecan  Hepatoma(HepG2, Hep1B)  Additive  Ocker, 2005
Vorinostat + Flavopiridol  Leukemia (U937)  Synergistic  Almenara, 2002
Vorinostat + Imatinib  CML (LAMA-84)  Additive  Nimmanapalli, 2002
Vorinostat + ATRA  APL (NB4)  Additive/Synergistic  He, 2001Biologics: Targets & Therapy 2007:1(4) 390
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